A Phase I Trial Testing Multiple Antigen-Engineered DC Followed by IFNa2b Boost for Immunization of HLA-Unrestricted Melanoma Patients
Latest Information Update: 18 Sep 2021
At a glance
- Drugs MART-1 tyrosinase MAGE A6-transduced dendritic cell vaccine (Primary) ; Interferon alpha-2b
- Indications Malignant melanoma
- Focus Adverse reactions
- 31 Aug 2017 Biomarkers information updated
- 30 Jun 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 25 Jun 2012 New trial record